الخصائص الأولية و استجابتها لدواء (Ticagrelor) في عينة من المرضى الأردنيين المصابين بمتلازمة انسداد الشرايين التاجية الحادة: دراسة مقطعية

2016/03/12

Baseline characteristics and response to ticagrelor among Jordanian patients with acute coronary syndrome: cross sectional study

 

Mohammad I. Almatarneh1, Al-Motassem Yousef2

  1. Electronic Health Solutions, Amman, Jordan
  2. University of Jordan, Faculty of Pharmacy

Abstract

 

Background: Ticagrelor is a representative of a new chemical drug class which inhibits P2Y12 receptors of platelets in a reversible non-competitive way. “Variability of response” or “resistance” to antiplatelet drugs is of remarkable importance.

 

Objectives: Examine the variability in anti-platelet effect of ticagrelor in ACS patients.

 

Methods: cross-sectional study included 34 individuals aimed to quantify the extent of variability in platelet aggregation response after 6 weeks of starting ticagrelor, platelet aggregation inhibition was tested using Multiplate®. Whole blood was measured using different ADP concentrations (5 µM, 20 µM). Parameters calculated were aggregation, velocity, and area under the curve (AUC).

 

Results: There were 2 patients considered to have high on treatment platelet reactivity (HTPR), 6 patients were at risk of bleeding, and 24 patients had optimum response at 20 µM ADP. Meanwhile, at 5 µM ADP 15 patients were considered at higher risk for bleeding, 18 patients were having optimum response, and no patients were considered at HTPR. For hypertension patients, AUC reading was almost significantly higher at 5 µM ADP (22.4 + 8.1 vs. 15.5 + 10.6, P=0.07), and significantly higher compared to non-hypertensive patients at 20 µM ADP (30.4 + 9 vs.  20.6 + 9.6, P= 0.008).

 

Conclusion: Ticagrelor decreases platelet aggregation effectively which is reflected by low on-treatment platelet reactivity, and increases the risk of major bleeding events. Therefore, cardiologists might be facing a new challenge in the future; to individualize the level of platelet inhibition in order to decrease thrombotic events without increasing bleeding.

 

Keywords: ACS, acute coronary syndrome, ticagrelor, Jordan, Multiplate.